Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment

Rishi Arora; Michelle T. Martin; Justin Boike; Sonalie Patel

doi:10.4254/wjh.v15.i2.318

Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment

Rishi Arora, Michelle T. Martin, Justin Boike, Sonalie Patel^*

^*Corresponding author for this work

Medicine, Hepatology Division

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals.

Original language	English (US)
Pages (from-to)	318-320
Number of pages	3
Journal	World Journal of Hepatology
Volume	15
Issue number	2
DOIs	https://doi.org/10.4254/wjh.v15.i2.318
State	Published - Feb 27 2023

Keywords

Direct-acting antivirals
Glecaprevir/ pibrentasvir
Hepatitis C virus
Liver transplantation
Ribavirin
Sofosbuvir

ASJC Scopus subject areas

Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4254/wjh.v15.i2.318

Cite this

@article{70cffdd3ba6d4e768d2fd6b8246ac577,

title = "Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment",

abstract = "Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals.",

keywords = "Direct-acting antivirals, Glecaprevir/ pibrentasvir, Hepatitis C virus, Liver transplantation, Ribavirin, Sofosbuvir",

author = "Rishi Arora and Martin, {Michelle T.} and Justin Boike and Sonalie Patel",

year = "2023",

month = feb,

day = "27",

doi = "10.4254/wjh.v15.i2.318",

language = "English (US)",

volume = "15",

pages = "318--320",

journal = "World Journal of Hepatology",

issn = "1948-5182",

publisher = "Baishideng Publishing Group",

number = "2",

}

TY - JOUR

T1 - Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment

AU - Arora, Rishi

AU - Martin, Michelle T.

AU - Boike, Justin

AU - Patel, Sonalie

PY - 2023/2/27

Y1 - 2023/2/27

N2 - Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals.

AB - Glecaprevir/pibrentasvir in combination with sofosbuvir may serve as a safe and effective option for treatment of recurrent hepatitis C virus post-liver transplant in patients who previously failed direct-acting antivirals.

KW - Direct-acting antivirals

KW - Glecaprevir/ pibrentasvir

KW - Hepatitis C virus

KW - Liver transplantation

KW - Ribavirin

KW - Sofosbuvir

UR - http://www.scopus.com/inward/record.url?scp=85149616779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149616779&partnerID=8YFLogxK

U2 - 10.4254/wjh.v15.i2.318

DO - 10.4254/wjh.v15.i2.318

M3 - Article

C2 - 36926235

AN - SCOPUS:85149616779

SN - 1948-5182

VL - 15

SP - 318

EP - 320

JO - World Journal of Hepatology

JF - World Journal of Hepatology

IS - 2

ER -

Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this